Please ensure Javascript is enabled for purposes of website accessibility

West Bank Town Becomes ‘Big Prison’ as Israel Fences It In

2 days ago

Trump Says He’s Willing to Let Migrant Farm Laborers Stay in US

2 days ago

US Electric Vehicle Tax Breaks Will Expire on Sept. 30

2 days ago

Eyeing Arctic Dominance, Trump Bill Earmarks $8.6 Billion for US Coast Guard Icebreakers

2 days ago

Trump’s Sweeping Tax-Cut and Spending Bill Wins Congressional Approval

2 days ago

Americans Celebrate Their Independence With Record-Breaking Travel Numbers

3 days ago

US Supreme Court to Decide Legality of Transgender School Sports Bans

3 days ago

Nvidia Set to Become the World’s Most Valuable Company in History

3 days ago

Poll: 41% in US ‘Extremely Proud’ to Be American, Near Historic Low

3 days ago
Moderna Starting Last Trial of COVID-19 Vaccine, Expects to Make up to 1 Billion Doses a Year
TLBBHMAP3-U010ALB5ANM-348f959abae2-512-300x300-1
By Jim Jakobs, Digital Producer
Published 5 years ago on
July 16, 2020

Share

Moderna is targeting July 27 to begin phase 3 testing of their COVID-19 vaccine. The company is looking for thousands of volunteers to participate.

The Cambridge, Massachusetts-based biotech company is the first to announce an estimated start date for phase 3 trials in the United States.

Newly released data from earlier human trials showed their vaccine candidate appears to be safe and provide some immunity. The most commonly reported systemic adverse events following second vaccination at the 100 microgram dose were fatigue (80%), chills (80%), headache (60%), and myalgia (53%), all of which were moderate in severity. The most common local adverse event at the 100 microgram dose was pain at the injection site (100%), which was also transient and mild or moderate in severity.

(Moderna Facebook)

New data from early trials shows Moderna’s COVID-19 vaccine candidate appears to be safe and provide some immunity.

Guidance for Vaccine Volunteers

Information about the trial, including guidance for vaccine volunteers, was posted on clinicaltrials.gov on Tuesday.

A brief summary posted on the site says, “The mRNA-1273 vaccine is being developed to prevent COVID-19, the disease resulting from Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) infection. The study is designed to primarily evaluate the efficacy, safety, and immunogenicity of mRNA-1273 to prevent COVID-19 for up to 2 years after the second dose of mRNA-1273.”

Moderna describes mRNA as like software for the cell; mRNA medicines are sets of instructions. And these instructions direct cells in the body to make proteins to prevent or fight disease.

Below is a video Moderna posted to its Facebook page describing the use of mRNA therapeutics.

For inclusion in the study, volunteers must meet several criteria including the following:

  • Participants who are at high risk of SARS-CoV-2 infection, defined as adults whose locations or circumstances put them at appreciable risk of exposure to SARS-CoV-2 and COVID-19.
  • Understands and agrees to comply with the study procedures and provides written informed consent.
  • Able to comply with study procedures based on the assessment of the Investigator.
  • Female participants of non-childbearing potential may be enrolled in the study.
  • Female participants of childbearing potential may be enrolled in the study if the participant fulfills all the following criteria:
    • Has a negative pregnancy test at Screening and on the day of the first dose (Day 1).
    • Has practiced adequate contraception or has abstained from all activities that could result in pregnancy for at least 28 days prior to the first dose (Day 1).
    • Has agreed to continue adequate contraception through three months following the second dose on Day 29.
    • Is not breastfeeding.
  • Male participants engaging in activity that could result in pregnancy of sexual partners must agree to practice adequate contraception and refrain from sperm donation from the time of the first dose and through three months after the second dose.
  • Healthy adults or adults with pre-existing medical conditions who are in stable condition. A stable medical condition is defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the three months before enrollment.

Moderna tweeted information and a link about the study Tuesday.

California Study Locations

Several locations throughout California will be utilized and volunteers will be needed for each.

  • Advanced Clinical Research, Rancho Paseo in Banning
  • University of California San Diego in La Jolla
  • eStudySite in La Mesa
  • UCLA Vine Street Clinic CRS  in Los Angeles
  • Paradigm Clinical Research Institute Inc. in Redding
  • Benchmark Research in Sacramento
  • Medical Center For Clinical Research, M3 Wake Research in San Diego

If you are interested, contact Moderna Clinical Trials at (855) 663-6762 or email clinicaltrials@modernatx.com

The randomized, placebo-controlled trial is expected to include approximately 30,000 participants at the 100 microgram dose level in the U.S.

Early Results Encouraging

Moderna’s experimental vaccine against the coronavirus showed encouraging results in early testing.

COVID-19 antibodies were found in all 45 participants, the biotech company announced in a May news release.

Neal Browning of Bothell, Washington, spoke to GV Wire via Zoom shortly after the early testing results were made public.

“I’m the second person to receive the vaccine in a small dose so that means I’ve got the antibodies,” Browning said. “One of the first people to reach out to me was Jennifer Haller, the lady who was the first to receive the vaccine. She was super excited, too. We chatted a little bit on text about that.”

Neal Browning becomes the second volunteer to receive the investigational COVID-19 vaccine in the NIH-supported clinical trial in Seattle. (AP File)

Moderna said the early vaccine data indicated that it provided full protection against viral replication in the lungs in a mouse challenge model.

An interim analysis just published in The New England Journal of Medicine shows mRNA-1273 induced rapid and strong immune responses against SARS-CoV-2.

In a press release, Moderna says, “After two vaccinations, mRNA-1273 elicited robust neutralizing antibody titers. At Day 43, neutralizing activity against SARS-CoV-2 was seen in all evaluated participants.”

Moderna has posted a video of a conference call on Wednesday providing more information to investors.

500 Million Doses a Year

Moderna is working closely with Operation Warp Speed and the NIH, including NIAID’s COVID-19 Prevention Trials Network to conduct the Phase 3 study.

With the Phase 3 dose being finalized at 100 micrograms, the company remains on track to be able to deliver approximately 500 million doses per year, and possibly up to 1 billion doses per year, beginning in 2021 from the company’s internal U.S. manufacturing site and strategic collaboration with Lonza.

In addition, Moderna recently announced a collaboration with Catalent for large-scale, commercial fill-finish manufacturing of mRNA-1273 at Catalent’s biologics facility in Indiana. On July 9, Moderna announced a collaboration with ROVI for large-scale, commercial fill-finish manufacturing of mRNA-1273 intended in principle to supply markets outside of the U.S. starting in early 2021 at ROVI’s facility in Madrid, Spain.

DON'T MISS

What Are Fresno Real Estate Experts Predicting for 2025 and Beyond?

DON'T MISS

First California EV Mandates Hit Automakers This Year. Most Are Not Even Close

DON'T MISS

How Trump’s ‘Big, Beautiful Bill’ Will Make China Great Again

DON'T MISS

What’s Caitlin Clark Worth to the WNBA? A Lot More Than Her $78,066 Salary.

DON'T MISS

Trump to Sign Tax-Cut and Spending Bill in July 4 Ceremony

DON'T MISS

Madre Fire Spurs Evacuations Across 3 Counties, Grows to More Than 70,000 Acres

DON'T MISS

Clovis, Sanger, Madera, and Bass Lake Will Light the Sky With Fireworks Shows Tonight

DON'T MISS

Oil Dips Ahead of Expected OPEC+ Output Increase

DON'T MISS

613 Killed at Gaza Aid Distribution Sites, Near Humanitarian Covoys, Says UN

DON'T MISS

Fresno County Authorities Investigating Suspicious Death of Transient Man

DON'T MISS

West Bank Town Becomes ‘Big Prison’ as Israel Fences It In

DON'T MISS

Israeli Military Kills 20 in Gaza as Trump Awaits Hamas Reply to Truce Proposal

UP NEXT

613 Killed at Gaza Aid Distribution Sites, Near Humanitarian Covoys, Says UN

UP NEXT

West Bank Town Becomes ‘Big Prison’ as Israel Fences It In

UP NEXT

Israeli Military Kills 20 in Gaza as Trump Awaits Hamas Reply to Truce Proposal

UP NEXT

Russia Pounds Kyiv With Largest Drone Attack, Hours After Trump-Putin Call

UP NEXT

Markets’ 90-Day Tariff Pause Rollercoaster Nears an Uncertain End

UP NEXT

Fresno Crash Involving Unlicensed Teen Driver Sends Woman to Hospital

UP NEXT

Madre Fire Burns More Than 52,000 Acres in San Luis Obispo County

UP NEXT

Eyeing Arctic Dominance, Trump Bill Earmarks $8.6 Billion for US Coast Guard Icebreakers

UP NEXT

Colombia President Recalls Ambassador to US

UP NEXT

US-Backed 60-Day Gaza Ceasefire Envisions Gradual Return of Hostages, Official Says

Madre Fire Spurs Evacuations Across 3 Counties, Grows to More Than 70,000 Acres

1 day ago

Clovis, Sanger, Madera, and Bass Lake Will Light the Sky With Fireworks Shows Tonight

1 day ago

Oil Dips Ahead of Expected OPEC+ Output Increase

2 days ago

613 Killed at Gaza Aid Distribution Sites, Near Humanitarian Covoys, Says UN

2 days ago

Fresno County Authorities Investigating Suspicious Death of Transient Man

2 days ago

West Bank Town Becomes ‘Big Prison’ as Israel Fences It In

2 days ago

Israeli Military Kills 20 in Gaza as Trump Awaits Hamas Reply to Truce Proposal

2 days ago

Valley Crime Stoppers’ Most Wanted Person of the Day: Rachelle Maria Blanco

2 days ago

Russia Pounds Kyiv With Largest Drone Attack, Hours After Trump-Putin Call

2 days ago

Boxer Chavez Jr Expected to Be Deported to Mexico to Serve Sentence, Mexican President Says

2 days ago

How Trump’s ‘Big, Beautiful Bill’ Will Make China Great Again

Can you hear it — that loud roar coming from the East? It’s the sound of 1.4 billion Chinese laughing at us. Thomas L. Friedman The New Yo...

15 hours ago

Solar Farm in Riesel, Texas
15 hours ago

How Trump’s ‘Big, Beautiful Bill’ Will Make China Great Again

Caitlin Clark Signs T-Shirt
15 hours ago

What’s Caitlin Clark Worth to the WNBA? A Lot More Than Her $78,066 Salary.

President Donald Trump speaks during a press conference in the Roosevelt Room at the White House in Washington, D.C., U.S., May 12, 2025. (Reuters File)
1 day ago

Trump to Sign Tax-Cut and Spending Bill in July 4 Ceremony

The Madre Fire burning near New Cuyama has scorched 70,801 acres as of Friday, July 4, 2025, afternoon, making it California’s largest wildfire of the year, with only 10% containment and multiple evacuation zones in place. (CalFire)
1 day ago

Madre Fire Spurs Evacuations Across 3 Counties, Grows to More Than 70,000 Acres

1 day ago

Clovis, Sanger, Madera, and Bass Lake Will Light the Sky With Fireworks Shows Tonight

A pumpjack operates at the Vermilion Energy site in Trigueres, France, June 14, 2024. (Reuters File)
2 days ago

Oil Dips Ahead of Expected OPEC+ Output Increase

Palestinians gather to collect what remains of relief supplies from the distribution center of the U.S.-backed Gaza Humanitarian Foundation, in Rafah, in the southern Gaza Strip, June 5, 2025. (Reuters File)
2 days ago

613 Killed at Gaza Aid Distribution Sites, Near Humanitarian Covoys, Says UN

Billy Wayne Sinisgalli, a 54-year-old transient known locally as Wayne, was found dead along a rural Fresno road Wednesday in what authorities are investigating as a suspicious death. (Fresno County SO)
2 days ago

Fresno County Authorities Investigating Suspicious Death of Transient Man

Help continue the work that gets you the news that matters most.

Search

Send this to a friend